FDA clears Roche Cobas c 703, Cobas ISE Neo
March 31, 2026—The Food and Drug Administration granted 510(k) clearance to Roche’s Cobas c 703 and Cobas ISE Neo analytical units.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Leica Biosystems launches next-gen Aperio GT Elite scanner
March 24, 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
Siemens Healthineers launches RUO blood-based tau assays
March 20, 2026—Siemens Healthineers has launched the Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived Tau assays for research use.
Roche mass spec steroid assays categorized as moderate complexity
March 18, 2026—Roche received CLIA moderate complexity categorization for its Ionify steroid assays for mass spectrometry.
FDA clears Qiagen GI panels on QIAstat-Dx Rise
March 13, 2026—The Food and Drug Administration has cleared the Qiagen QIAstat-Dx Gastrointestinal Panel 2 and QIAstat-Dx GI Panel 2 Mini B and Mini B&V for use on the QIAstat-Dx Rise automated syndromic testing system.
MeMed BV Flex gets breakthrough device designation
March 12, 2026—The FDA has granted breakthrough device designation to MeMed’s BV Flex, a blood test designed to distinguish between bacterial and viral infections based on the body’s immune response.
Biocartis gets European IVDR certification for Idylla CDx MSI test
March 11, 2026—Biocartis’ Idylla CDx MSI test has received class C companion diagnostic certification under the European Union IVDR.
Agilent to acquire Biocare Medical for $950 million
March 9, 2026—Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million.
Proscia earns top score in KLAS digital pathology report
March 4, 2026—A new report from KLAS Research awarded Proscia the highest overall performance score (95.2) in the U.S. market, based on customer feedback.
ARUP creates Innovation Central Laboratory
Feb. 26, 2026—ARUP Laboratories has launched the Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.